Arvinas’ ARV-471 is an orally bioavailable CRBN-based ER PROTAC degrader for treating patients with ER+/HER2-breast cancer and the first PROTAC to enter Ph. III clinical trials. This molecule one-pager serves as a reference guide, offering an overview of the scientific significance of Arvinas’ ARV-471 program. It includes links to key presentations, publications, patents, preclinical and clinical PK data summaries, and more.
Drug Hunter offers industry professionals a faster way to find and absorb the latest research and insights in drug discovery. It is a curated collection of the most relevant and transferable scientific knowledge so you can spend less time weeding through the noise and more time turning molecules into medicines. But we also love hearing from you, the drug hunters in the field.
Learning from industry leaders is one of the best ways to grow as a drug discovery professional. This table lists some of the top drug discovery blogs and biopharma social media influencers, all of whom are clearly passionate about their work. These are excellent, free resources that offer valuable insights and perspectives.
There are catalysis geniuses (looking at you, process chemists!) and then there are those of us just looking to put compounds in vials. Here are the simplest conditions that'll get you what you want 90% of the time. Beyond that you'll need to ask a guru like Nick White or Malcolm Huestis. Hope this table helps. Explore drughunter.co m for more.
Small-molecule drug candidates are increasingly falling “ beyond the rule of 5 ,” making oral administration more challenging. Optimizing a drug’s solid form can improve its solubility and bioavailability when further molecular modifications are prohibitive. This minireview covers solid form strategies for increasing the solubility and oral [...]